Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(+)-Abscisic acid (HB4674)
Description:Phytohormone and endogenous lanthionine synthetase C-like 2 (LANCL2) ligand
Purity:>99%
(±)-Anatoxin A fumarate (HB2023)
Description:Potent nicotinic agonist. Apoptosis inducer.
Purity:>99%
(±)-Bay K 8644 (HB1209)
Description:L-type Ca2+ channel agonist. Aids iPSCs generation from Mouse embryonic fibroblasts.
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
Deschloroclozapine (DCZ) (HB8555)
Description:Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator.
Purity:>98%